Furthermore, we aimed to provide evidence how treatment with CFTR correctors and potentiators could be monitored using HE4 as a plasma biomarker in routine clinical practice and what the particular diagnostic value of HE4 is in monitoring degree of decreased inflammation in CF patients due to restored function of CFTR. This evidence concerns the gene CFTR and cystic fibrosis.